1192-17-2Relevant articles and documents
Molybdenum containing surface complex for olefin epoxidation
Yang, Qihua,Coperet, Christophe,Li, Can,Basset, Jean-Marie
, p. 319 - 323 (2003)
Silica-supported molybdenum surface complexes were prepared by the reaction between (N≡)Mo(OtBu)3 and silica via displacement of the tert-butoxy ligands for siloxyls from the silica surface. The structure of the surface molybdenum complexes was well defined by in-situ FT-IR, elemental analysis, 1H NMR and 13C CP/MAS NMR techniques. The surface complexes could undergo alcoholysis reaction with CD3OD and CH3OH in the same way as free (N≡)Mo(OtBu)3 and they show high catalytic activity and selectivity in olefin epoxidation. Initial rates up to 24.9 mmol epoxide (mmol Mo)-1 min-1 were achieved in the epoxidation of cyclohexene using TBHP as oxidant.
Regioselective Carbonylation of 2,2-Disubstituted Epoxides: An Alternative Route to Ketone-Based Aldol Products
Hubbell, Aran K.,Lapointe, Anne M.,Lamb, Jessica R.,Coates, Geoffrey W.
supporting information, p. 2474 - 2480 (2019/02/14)
We report the regioselective carbonylation of 2,2-disubstituted epoxides to β,β-disubstituted β-lactones. Mechanistic studies revealed epoxide ring-opening as the turnover limiting step, an insight that facilitated the development of improved reaction conditions using weakly donating, ethereal solvents. A wide range of epoxides can be carbonylated to β-lactones, which are subsequently ring-opened to produce ketone-based aldol adducts, providing an alternative to the Mukaiyama aldol reaction. Enantiopure epoxides were demonstrated to undergo the carbonylation/ring-opening process with retention of stereochemistry to form enantiopure β-hydroxy esters.
AMIDE DERIVATIVES FOR GPR119 AGONIST
-
Page/Page column 35, (2015/06/11)
The present invention relates to novel amide derivatives, stereoisomers thereof or pharmaceutically acceptable salts thereof; methods for preparing the compound; and pharmaceutical compositions comprising the compound. The novel amide derivatives, according to the present invention, having an effect as GPR119 agonist can be used for treatment of metabolic disorders, including diabetes mellitus (especially type II) and related disorders.